Recent Updates
Recently added Catalysts
BEAM Positive Sentiment

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Beam Therapeutics presented updated clinical data for BEAM-302 at the ERS Congress 2026. The trial indicates that BEAM-302 may serve as a one-time treatment for Alpha-1 Antitrypsin Deficiency (AATD), effectively addressing both lung and liver manifestations. Data show sustained AAT protein production under normal physiological control with follow-up extending up to 18 months.

Market Sentiment Analysis

POSITIVE FACTORS

  • BEAM-302 shows potential as a one-time treatment.
  • Demonstrated long-term durability in correcting disease-causing mutations.
  • Effective for both lung and liver manifestations of AATD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
8.7%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
BEAM-302
Phase 1 · Alpha 1-Antitrypsin Deficiency

Full Press Release Details

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with

Frequently Asked Questions

What is BEAM-302?

BEAM-302 is a treatment being studied for Alpha-1 Antitrypsin Deficiency (AATD).

What were the results of the BEAM-302 trial?

The trial showed long-term durability in correcting disease-causing mutations.

How long was the follow-up for the BEAM-302 trial?

The follow-up for the trial extended up to 18 months.

What manifestations of AATD does BEAM-302 address?

BEAM-302 addresses both lung and liver manifestations of AATD.

ShareAdd on Google
Tags: BEAM Viatris Investor Conferences Healthcare Beam Therapeutics AATD BEAM-302 clinical trial European Respiratory Society
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$1153M liquidity · $22M/mo burn
~51 mo
Minimal dilution risk
Lead asset
BEAM-302Phase 1
Alpha 1-Antitrypsin Deficiency →

Catalyst track record

+52%
best trade around BEAM's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for BEAM.

See every catalyst's timing & PoA →